Marek Petecki


Marek is a partner in the corporate practice and advises companies and investors who are active in IP-rich sectors; in particular the life sciences, technology and consumer products sectors.

Marek has a broad transactional practice that includes debt and equity financings, M&A, spin-outs, joint ventures, restructurings and complex commercial agreements.

Marek’s clients include several of the world’s largest biopharmaceutical and technology companies, as well as fast-growing companies and specialist investors.


  • BA History & Anthropology, University College London
  • Qualified 2003
  • Partner 2010
  • Joint Managing Partner 2016-2022


Biotech Review of the Year

Read here

What others say

“Marek Petecki is a superb lawyer, client relationship partner and team leader. We had to navigate some challenging issues which required not just legal knowledge but also valuable guidance in how best to implement the advice.” Legal 500 2024
“Marek Petecki is considered and thoughtful, humble, engaged, creative and direct.” Legal 500 2024
“Marek Petecki – very user friendly and all round great chap.” Legal 500 2024
“Marek Petecki ‘knows the VC and life sciences industry inside out’ and is a key practitioner within the team.” Legal 500 2023
“Very effective negotiator and organiser of teams of large transactions.” Legal 500 2022
“Stand out nice guy and totally on top of his game.” Legal 500 2022
"Marek Petecki is knowledgeable about finance, commercial contracts and M&A, and is a well-known name among global bio-pharma and technology companies." Legal 500 2021
"The ‘highly responsive, commercial’ Marek Petecki is a ‘standout partner’ who ‘finds and communicates practicable solutions to issues, and tailors his work carefully’; he is noted for his strength in M&A involving IP and technology. Petecki’s highlights included advising AstraZeneca on the £135m sale of its pharmaceutical manufacturing facility in Avonmouth to Avara." Legal 500 2017
"Marek Petecki advised Diageo on a joint venture with entrepreneur Piers Adam to develop a new whisky brand, Copper Dog, among other matters." Legal 500 2017

Recommended For

Venture Capital

Life Sciences and Healthcare

M&A: Smaller Deals, £10m-£100m

M&A: smaller deals up to £50m

Commercial Contracts

Related Articles